Supp ressors
LLV: Suppressed time poin t
LLV: LLV time poin
t
0 2,000 4,000 6,000 8,000 10,000 12,000
Nevirapine concentrations ng/mL
Bull et al., Supplemental Figure 1
18
Pw Diversity
PBMC Plasm
a
Plasma Mo 2 1
Plasma Mo 2 0.00 4
0.05 0.10 0.15
20
Pw Diversity
PBMC
Plasma Mo 1 0.00 2
0.05 0.10
0.15 26
Pw Diversity
PBM C
Plasma
Plasma Mo 1 8
Plasma Mo 2 0.00 1
0.02 0.04 0.06 0.08 0.10
34
Pw Diversity
PBMC Plasm
a
Plasma Mo 1 2
Plasma Mo 1 0.00 8
0.02 0.04 0.06 0.08
0.10 36
Pw Diversity
PBM C
Plasma
Plasma Mo 1 2
Plasma Mo 2 1 0.00
0.02 0.04 0.06 0.08
0.10 39
PBM C
Plasma
Plasma Mo 9
Plasma Mo 1 0.00 8
0.02 0.04 0.06 0.08 0.10
Pw Diversity
42
PBM C
Plasma
Plasma Mo 1 2
Plasma Mo 1 5 0.00
0.02 0.04 0.06 0.08 0.10
Pw Diversity
50
Pw Diversity
PBMC Plasma
Plasma Mo 0.00 9
0.02 0.04 0.06 0.08 0.10
51
Pw Diversity
PBMC Plasma
Plasma Mo 0.00 9
0.02 0.04 0.06 0.08 0.10
Bull et al. Supplemental Figure 2, Panel A
Mo 0 Mo 0 Mo 0
Mo 0 Mo 0 Mo 0
Mo 0 Mo 0 Mo 0
56
PBM C
Plasma
Plasma Mo 2 1
Plasma Mo 2 4 0.00
0.05 0.10 0.15
Pw Diversity
71
Pw Diversity
PBM C
Plasm a
Plasma Mo 1 0.00 2
0.02 0.04 0.06 0.08
0.10 80
Pw Diversity
PBM C
Plasm a
Plasma Mo 0.00 9
0.02 0.04 0.06 0.08 0.10
89
Pw Diversity
PBMC Plasma
Plasma Mo 1 2
Plasma Mo 1 0.00 8
0.02 0.04 0.06 0.08
0.10 98
Pw Diversity
PBMC Plasma
Plasma Mo 9
Plasma Mo 2 0.00 4
0.05 0.10
0.15 120
Pw Diversity
PBM C
Plasma Mo 1 0.00 2
0.02 0.04 0.06 0.08 0.10
125
Pw Diversity
PBMC Plasm
a
Plasma Mo 2 0.00 1
0.02 0.04 0.06 0.08 0.10
Bull et al. Supplemental Figure 2, Panel B
Mo 0 Mo 0 Mo 0
Mo 0 Mo 0 Mo 0
Mo 0
15
Pw Diversity
PBMC Plasm
a
Plasma Mo 0.00 6
0.05 0.10
0.15 21
Pw Diversity
PBM C
Plasm a
Plasma Mo 1 8 0.00
0.02 0.04 0.06 0.08
0.10 24
Pw Diversity
PBM C
Plasma
Plasma Mo 1 0.00 2
0.02 0.04 0.06 0.08 0.10
44
Pw Diversity
PBMC Plasm
a
Plasma Mo 1 2
Plasma Mo 2 1 0.00
0.02 0.04 0.06 0.08
0.10 47
Pw Diversity
PBMC Plasma Plasma Mo
9
Plasma Mo 1 2
Plasma Mo 2 0.00 1
0.02 0.04 0.06 0.08
0.10 58
PBM C
Plasma Plasma Mo
9
Plasma Mo 1 0.00 5
0.02 0.04 0.06 0.08 0.10
Pw Diversity
61
Pw Diversity
PBMC Plasma
Plasma Mo 9 Plasma Mo 2 1 0.00
0.02 0.04 0.06 0.08
0.10 81
Pw Diversity
PBMC Plasma
Plasma Mo 1 0.00 2
0.02 0.04 0.06 0.08
0.10 91
Pw Diversity
PBMC Plasma
Plasma Mo 1 8
Plasma Mo 2 0.00 4
0.02 0.04 0.06 0.08 0.10
Bull et al. Supplemental Figure 2, Panel C
Mo 0 Mo 0
Mo 0
Mo 0 Mo 0
Mo 0
Mo 0 Mo 0 Mo 0
92
Pw Diversity
PBMC Plasma
Plasma Mo 1 0.00 2
0.02 0.04 0.06 0.08
0.10 115
Pw Diversity
PBM C
Plasm a
Plasma Mo 1 0.00 8
0.05 0.10 0.15
Bull et al. Supplemental Figure 2, Panel D
Mo 0 Mo 0
Supplemental Figure 1: Quantification of plasma nevirapine (NVP) concentrations in participants with and without LLV. NVP concentrations were compared in specimens within participants when ART-suppressed and at LLV, and across participants at time-points with and without LLV. The NVP concentrations were similar in participants with and without LLV detected during the study; and in the former, both at LLV time-points and time-points when their plasma HIV RNA was <30c/mL.
Supplemental Figure 2: Phylogenetic HIV pairwise env diversity from participants evaluated for
low-level viremias (LLV) grouped by phylogenetic pattern into those with (A) monotypic pattern
#1 and with (B) a diverse pattern #2. Single genome amplicons (SGA) were generated as described in methods and sequences aligned using the MUSCLE algorithm in Geneious (BioMatters, Newark, NJ) and employed PhyML in DIVEIN [18] to generate maximum likelihood trees and pair-wise diversity (pwDiversity).
